| Print
VALERIO TX (ALVIO)
VALERIO THERAPEUTICSThis share can be held in a Dealing account
Company profile
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Onxeo SA Second Quarter Earnings Results for 2024 | 2024-09-27T00:00:00 |
| Onxeo SA Annual General Meeting for 2023 | 2024-06-06T14:00:00 |
| Onxeo SA Annual Report for 2023 | 2024-05-03T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Onxeo SA Annual Report for 2023 | 2024-05-03T00:00:00 |
| Onxeo SA Fourth Quarter Earnings Results for 2023 | 2024-04-19T00:00:00 |
| Onxeo SA Second Quarter Earnings Results for 2023 | 2023-09-28T00:00:00 |
| Onxeo SA Annual General Meeting for 2022 | 2023-06-06T14:00:00 |
| Onxeo SA Annual Report for 2022 | 2023-05-03T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.